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Hypertensioniation studies (GWAS) have identiﬁed DNA sequence variations that exhibit
unequivocal statistical associations with many common chronic diseases. However, the vast majority of these
studies identiﬁed variations that explain only a very small fraction of disease burden in the population at
large, suggesting that other factors, such as multiple rare or low-penetrance variations and interacting
environmental factors, are major contributors to disease susceptibility. Identifying multiple low-penetrance
variations (or “polygenes”) contributing to disease susceptibility will be difﬁcult. We present a pathway
analysis approach to characterizing the likely polygenic basis of seven common diseases using the Wellcome
Trust Case Control Consortium (WTCCC) GWAS results. We identify numerous pathways implicated in
disease predisposition that would have not been revealed using standard single-locus GWAS statistical
analysis criteria. Many of these pathways have long been assumed to contain polymorphic genes that lead to
disease predisposition. Additionally, we analyze the genetic relationships between the seven diseases, and
based upon similarities with respect to the associated genes and pathways affected in each, propose a new
way of categorizing the diseases.
© 2008 Elsevier Inc. All rights reserved.Introduction
Initial results from single-locus-based genome-wide association
studies (GWAS) analyses suggest that only aminority of DNA sequence
variations that modulate disease susceptibility will be identiﬁable
within the GWAS framework. The reasons for this are numerous and
likely reﬂect the fact that most common chronic diseases are
inﬂuenced by a number of rare and/or low-penetrance variations
that interact with environmental factors in complicated ways [1].
Thus, the very small fraction of both the heritable component and the
population disease burden explained by the few polymorphisms
identiﬁed as statistically signiﬁcant in recent GWAS initiatives
indicates that a large number of risk alleles-the vast majority of
which are not likely to have odds ratios greater than 1.3-are effectively
invisible to current single-locus GWAS analysis methods [1,2].
However, it is likely that alternative analysis approaches to GWAS
data that focus on the combined effects of many loci, each making a
small contribution to overall disease susceptibility, may reveal
insights into the genetic basis of common chronic disease. For
example, it is highly probable that univariate, single-locus analysis
results contain informative trends that, when viewed in the contextsl rights reserved.of genetic networks and fundamental molecular pathways, can expose
aspects of the polygenic basis of disease susceptibility. Although a few
methods have been proposed for detecting gene-gene interactions in
GWAS initiatives [3–5], both their use and comprehensiveness is
limited. In addition, it is not yet known whether overt interaction
effects contribute as much to the expression of a phenotype as the
combined, additive effects of many variations each with small
individual (i.e., polygenic) effects. The availability of the Wellcome
Trust Case Control Consortium (WTCCC) GWAS data and single-locus
analysis results [6] provides an excellent opportunity to develop and
test more comprehensive multilocus analysis methods designed to
tease out aspects of the polygenic basis of disease from GWAS data,
and hence may provide insights into the combined effects of low-
penetrance variations underlying disease susceptibility.
One approach to pathway-based analyses of GWAS data involves
converting the data to a form amenable to analyses with tools
developed for the interpretation of microarray-based gene expression
studies. In this light, we used the pathway and network analysis tools
provided in the MetaCore software suite developed by GeneGo (www.
genego.com). Essentially, SNPs are assigned to genes based upon their
proximity to open reading frames, and gene weights-as determined
from single-locus association test statistic data arising from a GWAS
analysis-are assigned to each gene (see Methods for details). Trends
identiﬁed from these gene-speciﬁc data that correspond, are con-
sistent with, or reveal particular networks or pathways can then be
tested for their statistical signiﬁcance. The goal of such an analysis is to
Table 2
Signiﬁcantly overrepresented pathways for the bipolar GWAS
Pathway p-value
Heparan sulfate and heparin metabolism 0.01
Cytoskeleton remodeling_Alpha-1A adrenergic receptor-dependent
inhibition of PI3K
0.01
Niacin-HDL metabolism 0.03
Neurophysiological process _Glutamate regulation of Dopamine D1A
receptor signaling
0.04
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disease tend to aggregate or cluster in biological pathways and
networks that are of biological relevance to the disease.
Ultimately, we demonstrate that pathway-based approaches are a
powerful means of overcoming the limitations imposed by univariate,
single-locus analysis of GWAS data and offer a powerful methodology
for revealing the polygenic nature of common chronic disease
susceptibility. Our analyses considered the WTCCC GWAS data,
which includes data from studies of bipolar disorder (BD), coronary
artery disease (CAD), Crohn’s disease (CD), hypertension (HT),
rheumatoid arthritis (RA), type 1 diabetes (T1D), and type 2 diabetes
(T2D). Our analyses of these diseases expose pathways long known to
be involved in disease pathogenesis, such as dopamine signaling in
hypertension, but for which causative common variations have not
yet been identiﬁed. Additionally, comparison of pathways and
processes implicated in different diseases reveals surprising insights
into shared genetic bases underlying seemingly unrelated diseases
and indicates a potential novel class structure in the categorization of
these diseases.
Results
Disease relationships
The correlations between the seven diseases, based upon the
negative log of p-values for genes, adjusted for the number of SNPs
mapping to each gene, is presented in upper diagonal entries of Table
1 (see the Methods section for details about the calculations). The
lower diagonal of Table 1 presents the number of SNPs shared in
common among the top-ranked 1000, in terms of statistical
signiﬁcance, SNPs per disease. The large number of SNPs shared in
common among all the diseases reveals strong relationships between
all the diseases considered. For comparison, the number of SNPs
expected to be shared in common by maximum likelihood, according
to the hypergeometric distribution, is 2. Thus, all disease relationships
are strongly signiﬁcant (pb0.0001 based on the hypergeometric
distribution). Similar calculations using Pearson correlation coefﬁ-
cients over the SNPs to measure similarity in the ﬁndings across the
different diseases also suggest the existence of relationships between
the diseases. For example, strong correlations between the metabolic
disorders CAD and T2D, as well as the autoimmune-system-related
disorders RA and T1D, were observed, as would be expected by their
known etiologies. It should be emphasized, however, that these
correlations involve SNPs whose test statistics did not reach genome-
wide signiﬁcance levels and hence would have been considered
potential false positive results if not viewed in a polygenic context.
However, some surprises were also observed. For example, a strong
genetic correlation of BD with the metabolic disorders CAD and T2D,Table 1
Relationships between the seven diseases based on the GWAS results
BD CAD CD HT RA T1D T2D
BD 1 0.54 0.06 0.08 0.03† 0.02† 0.85
CAD 58 1 0.02† 0.04 0.22 0.014Ψ 0.51
CD 48 40 1 0.23 0.09 0.09 0.09
HT 85 63 40 1 0.12 0.05 0.11
RA 36 55 39 37 1 0.35 0.02‡
T1D 22 21 44 24 268 1 0.02‡
T2D 68 57 45 81 39 30 1
Notes. Upper diagonal contains Pearson correlation coefﬁcients. Lower diagonal
contains the number of SNPs shared in common amongst the top 1000 most
signiﬁcant SNPS per disease.
All unmarked pb0.0001.
† pb0.003.
‡ pb0.02.
Ψ Not signiﬁcant.as well as a strong correlation between HT and CD-seemingly
unrelated diseases-was observed. These relationships are seen both
from an analysis based on correlations between SNP test statistics
(upper diagonal) and from an analysis based on the fraction of high-
ranking SNPs in common for each pair of diseases (lower diagonal). In
fact, the two different measures of the relationships between diseases
themselves are correlated (r2=0.449127, p=0.0411 (Pearson’s’ correla-
tion); r2=0.64, p=0.0018 (Spearman’s correlation)). This suggests
some unexpected links between these diseases, which will be
considered further in the analysis of each disease described in
isolation below.
Bipolar disorder
Supplemental Table 1 presents the top 10 disease pathways
enriched among the most signiﬁcant SNPs identiﬁed in the bipolar
disorder data, which clearly implicate mood and neurological disorder
disease pathways. The signaling pathways enriched in bipolar
disorder are presented in Table 2. Notably, regulation of dopamine
signaling is a signiﬁcant pathway. Although a great deal of research
has explored a direct link between the regulation of dopamine
signaling and mood disorders, there has been little success in
identifying statistically compelling associations with particular varia-
tions in genes involved in dopamine signaling andmood disorders. On
the other hand, the successful targeting of these pathways by drugs
used to treat bipolar disorder strongly suggests that a link between
dopamine signaling and bipolar disorder must exist [7]. Proteins
identiﬁed as signiﬁcant from the BD analysis within this pathway are
the AMPA receptor and the GABA-A receptor beta-1 and beta-3
subunits, as well as PP2A. The biological processes enriched in the BD
data (Supplemental Table 2) further implicate glutamatergic signaling
and nervous system development, and the occurrence of these
pathologies within a BD population validates their importance as
putative genetic factors implicated in BD pathogenesis.
The ﬁrst signiﬁcant pathway, heparan sulfate, contains the
associated gene EXTL1, a glucosyltransferase, as well as three
sulfotransferase proteins, all of which are expressed in the brain:
NDST3, HS6ST3, and HS6ST1. Sulfotransferase activity inactivates
dopamine by sulfation and is induced in an animal model of psychotic
mania, and it is thought that suﬂotransferase defects may impair
clearing of dopamine from the extracellular space surrounding
neurons [8]. Additionally, two other sulfotransferases, SULT1A1 and
DSEL, have been linked to bipolar disorder [9]. Our ﬁnding provides
more interesting leads for the role of sulfotransferases in mood
disorders and their likely effects on dopamine signaling.
The niacin-HDL metabolism and adrenergic receptor-mediated
cytoskeletal remodeling pathways provide an intriguing link between
BD and metabolic disorders, as conﬁrmed by the high degree of
correlation between the BD and CAD and T2D GWAS results described
in Table 1. In addition to the obvious link between HDL metabolism
and metabolic syndrome, both alpha and beta adrenergic signaling
have been implicated inmetabolic syndrome [10]. In fact, a reasonably
high prevalence of metabolic syndrome in patients with bipolar
disorder has been observed [11], strongly suggesting a genetic
relationship between mood disorders and metabolic disorders.
Table 4
Signiﬁcantly overrepresented pathways for the Crohn’s disease GWAS
Pathway p-value
Signal transduction_Calcium signaling 0.008
Transcription_ChREBP regulation pathway 0.01
Immune response _IL3 activation and signaling pathway 0.02
Regulation of lipid metabolism_Regulation of acetyl-CoA
carboxylase 1 activity in keratinocytes
0.03
Regulation of lipid metabolism_Regulation of acetyl-CoA
carboxylase 1 activity in lipogenic tissue
0.03
Immune response _IFN alpha/beta signaling pathway 0.03
Immune response _IL2 activation and signaling pathway 0.04
Development_Role of CDK5 in neuronal development 0.04
Immune response _Antigen presentation by MHC class II 0.05
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Genome-wide association studies have had little success in
identifying genes underlying coronary artery disease (CAD), although
diabetes, obesity, andmetabolic syndrome arewell-known risk factors
for CAD. Analysis of enriched processes among the most strongly
associated genes in the CAD data (Supplemental Table 3) reveals great
biochemical and physiologic complexity underlying CAD. However,
the dominant processes appear to target contractile functions of
vascular smooth muscle cells (VSMC), ranging from cytoskeleton
rearrangement to cell adhesion and matrix interactions, development
of synapses and neuromuscular junctions, control of neurotransmis-
sion and smooth muscle contractions, and calcium signaling. Most of
these processes, especially cell adhesion, matrix interaction, and
neuronal factors, have been shown to be important for differentiation
of VSMC from migratory to contractile cells [12]. This suggests that
genetic defects in these processes may inhibit the contractile
phenotype of VSMC and favor phenotypic switching to the migratory
VSMC phenotype, a key process in atherosclerosis [12].
While the enriched biological processes among the most strongly
CAD-associated genes point toward developmental defects underlying
CAD, pathway analysis (Table 3) provides evidence for a series of
mechanisms in which the Tubby (TUB) gene plays a central role. Loss
of Tubby function mutants lead to obesity in mice [13], strongly
implicating this pathway inmetabolic aspects of CAD. However, Tubby
itself does not appear as a signiﬁcant gene in our analysis; rather,
PLCG2, which modulates insulin signaling through Tubby [14], and G-
protein GNG2, which modulates Serotonin signaling through Tubby
[15], as well as PRKCH, are among the highest-ranking genes in our
analysis. The serotonin signaling pathway is also implicated in our
pathway analysis of CAD, and the high correlation between BAD and
the BD GWAS results, as well as the strong association of depressive
symptoms with cardiac events, lends support to the interesting
possibility that common genetic mechanisms may underlie the two
disease phenotypes [16]. Tubby signaling members PRKCH and PLCG2
are also involved in VEGF signaling, and another associated gene in
that pathway, TEK, appears in our analysis, suggesting that a real
genetic link between coronary artery disease and defects in
angiogenesis may exist [17].
Finally, calcium signaling appears to play a role in CAD. Calcium
channel constituents CACNA1C, CACNA2D3, CACNB4, and CACNG1 are
all affected in the CAD data. Calcium and IP3 signaling are interrelated,
andwithin these pathways we observe PLCG2 and CAMK2D, as well as
MEF2B and MEF2A. MEF2A gene variations have already been
implicated in early onset CAD [18], suggesting that these four highly
interconnected pathways contain genes that, when perturbed, may
mediate CAD.
Crohn’s disease
CD is an immunologically mediated inﬂammatory condition, and
the results of our pathway analysis of the most strongly associated
genes with CD provide insights into speciﬁc immunological pathways
that might be altered in CD. A number of pathways support the
established hypothesis of aberrant T-cell responses in CD, especially
defects in MHC-class II signaling through HLA-DRA to T-helper cells
(Table 4). In addition, we observe pathway hits in calcium signaling,Table 3
Signiﬁcantly overrepresented pathways for the CAD GWAS
Pathway p-value
Transcription_Transcription factor Tubby signaling pathways 0.01
Signal transduction_Calcium signaling 0.01
Development_Cross-talk VEGF and angiopoietin 1signaling 0.02
Signal transduction_IP3 signaling 0.03speciﬁcally at RHOA, AKAP6, and calcium channels CACNA1C and
CACNA2D3, all of which modulate calcium levels, which, in turn,
through calcineurin signaling, regulate the transcriptional activity of
another associated gene in the calcium signaling pathway, NF-AT
(NFATC1). NF-AT is a central element in T-cell differentiation and
proliferation [19]. NF-AT binds to DNA cooperatively with other
transcription factor hits in both the IL2 and IL3 signaling pathways,
namely AP-1 (FOSL2) and OCT1 (POU2F1) [20]. Interferon signaling is
also affected by genes involved in interferon alpha/beta regulatory
factors: IRF1, IRF2, and interferon-induced protein IFI6.
While genes that mediate immunological defects were expected to
be among the most strongly associated with CD, surprisingly, a
number of metabolic pathways, especially lipid metabolism, are
enriched in the CD GWAS most strongly associated genes, all of which
include the common pathway hits AMPK gamma and alpha (PRKAG2,
PRKAA1) (discussed in detail in the Supplemental Text). These
metabolic defects suggest a basis for the genetic relationship between
CD and both BD and CAD (Table 1), which is observed to be stronger
than the correlation of CDwith other autoimmune diseases (e.g., T1D).
Hypertension
Although a lack of genome-wide signiﬁcant associations was
observed for hypertension (HT) in the original WTCCC GWAS, a long
list of signiﬁcant and interconnected pathways was detected by our
analysis of the most strongly associated SNPs from the GWAS of HT.
The apparent high degree of interconnection between these pathways
suggests that multiple, but related, mechanisms are likely to underlie
hypertension susceptibility and, furthermore, demonstrates that a
large number of common but low-penetrance risk alleles are likely to
be involved.
The most signiﬁcant pathway overrepresented in the genes most
strongly associated with HT suggests a role for defects in dopamine
signaling (see Table 5). Speciﬁcally, genes that we ﬁnd among themost
strongly associated with HT include the AMPA receptor (GRIA4),
NMDA receptor (GRIN2A), and GABA-A receptor (GABRB3) (receptors
that play a role in the cytoskeletal remodeling of synapses in response
to EphB signaling, whichmay be unrelated to hypertension), as well as
ADCY5, GNAS, PPP3CA, and PRKAR2B. Dopamine signaling has a well-
established role in regulating blood pressure via a number of
mechanisms, including regulation of vascular smooth muscle tone
[21], which is another pathway signiﬁcantly overrepresented in our
analysis, and encompasses the receptor subunits CHRM2 and HTR2A,
as well as ADCY4, ADCY5, GNAS, PRKAR2B, and CAMK2D.
These key members (ADCY4, ADCY5, GNAS, PRKAR2B, CAMK2D)
also play a role in awide variety of interconnected pathways including
PKA signaling and cAMP signaling, as well as the development of
alpha- and beta-adrenergic receptor signaling, which have well-
established roles in the control of blood pressure. Additionally, they
are involved in pathways directly implicated in regulating blood
pressure, including PGE2 signaling [22] and calcium signaling, with
Table 6
Signiﬁcantly overrepresented pathways for the rheumatoid arthritis GWAS
Pathway p-value
Immune response _MIF - the neuroendocrine-macrophage connector 0.001
Signal transduction_Calcium signaling 0.003
Development_Angiotensin activation of Akt (AKT1) 0.004
Signal transduction_IP3 signaling 0.009
Regulation of lipid metabolism_PDGF activation of prostacyclin
synthesis
0.01
Signal transduction_cAMP signaling 0.01
Development_Cross-talk VEGF and angiopoietin 1signaling 0.02
Development_EDNRB signaling 0.02
Development_VEGF signaling via VEGFR2 - generic cascades 0.02
Immune response _NF-AT signaling and leukocyte interactions 0.02
Cell adhesion_Histamine H1 receptor signaling in the interruption
of cell barrier integrity
0.03
Immune response _Function MEF2 in T lymphocytes 0.03
Immune response _Histamine signaling in dendritic cells 0.03
Development_Angiotensin activation of ERK (MAPK1) 0.03
Immune response _PGE2 common pathways 0.03
Transport_Membrane trafﬁcking and signal transduction of
G-alpha (i) heterotrimeric G-protein
0.04
Cytoskeleton remodeling_Role PKA in cytoskeleton reorganization 0.05
Table 5
Signiﬁcantly Overrepresented Pathways for the Hypertension GWAS
Pathway p-value
Neurophysiological process _Glutamate regulation of Dopamine
D1A receptor signaling
0.0002
Regulation of lipid metabolism_Regulation of lipid metabolism
by niacin and isoprenaline
0.0005
Signal transduction_cAMP signaling 0.002
Cell adhesion_Endothelial cell contacts by non-junctional mechanisms 0.002
Immune response _MIF - the neuroendocrine-macrophage connector 0.004
Immune response _PGE2-induced pain processing 0.008
Apoptosis and survival_BAD phosphorylation 0.01
Signal transduction_PKA signaling 0.01
Transcription_ChREBP regulation pathway 0.01
Development_Alpha-1 adrenergic receptors signaling via cAMP 0.02
Cell adhesion_Endothelial cell contacts by junctional mechanisms 0.02
Muscle contraction_ GPCRs in the regulation of smooth muscle tone 0.02
Cytoskeleton remodeling_EphB receptors in dendritic spine
morphogenesis and synaptogenesis
0.02
Cell cycle_Chromosome condensation in prometaphase 0.03
Cytoskeleton remodeling_Role PKA in cytoskeleton reorganization 0.03
Signal transduction_Calcium signaling 0.04
Plasmalogen biosynthesis 0.04
Immune response _PGE2 signaling in immune response 0.04
Development_Beta-adrenergic receptors regulation of ERK 0.04
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calcipressin (RCAN2). Calcineurin inhibitors are known to increase
blood pressure [23]. Calcineurin signaling, along with the previously
mentioned key members, is also involved in the regulation of lipid
metabolism, likely underlying the metabolic defects associated with
hypertension risk. Glucose metabolism is also affected through
ChREBP (MLXIPL) regulation with an additional hit in ACSL5. An
unrelated pathway, plasmalogen biosynthesis, which is implicated in
the control of lipoprotein levels, provides an additional genetic
mechanism for metabolic defect in hypertension, with pathway
members among the most signiﬁcantly associated genes including
PLD1, PLA2G1B, and AGPS [24].
Finally, genetic defects in cell-cell interactions and cytoskeletal
remodeling due to cell-cell signaling, as well as particular interactions
between endothelial cells and smooth muscle cells, are implicated in
this analysis, with associated genes Alpha-3/Beta-1 integrin (ITGA3),
Collagen IV (COL4A2), Claudin-14 (CLDN14), ACTN2, CTNNA3, and
MAGI1. Genetic perturbations in these cell-cell interactions suggest a
complimentary defect in the maintenance of vascular smooth muscle
tone.
The evidence for the involvement of additional pathways in
hypertension is sparse, but provides some interesting leads. Recent
evidence, consistent with our analysis results, implicate chromosome
condensation and apoptosis as potential pathogenic mechanisms [25].
Another interesting set of genes among the most strongly associated
implicates macrophage inhibitory factor signaling, which include the
associated genes mentioned above, as well as plasminogen PLA2G1B
and CSNK2A2. A provocative connection betweenMIF and angiotensin
II in spontaneously hypertensive rats has recently been observed [26].
Obviously, it will be interesting to see if further studies will verify the
biological signiﬁcance of these results.
The connection of MIF signaling and PGE2 processes involved in
immune function may provide hints into the strong correlation
between HT and CD and RA demonstrated in Table 1 [27]. Over-
represented biological processes for both diseases show great
similarities and are presented in Supplemental Table 5.
Rheumatoid arthritis
Rheumatoid arthritis (RA) is an autoimmune disease characterized
by synovial inﬂammation and destruction of multiple joints. As would
be expected, autoimmune diseases dominate the most overrepre-sented diseases among those associated with the most strongly
associated RA genes, and immune functions dominate the most
overrepresented processes (Supplemental Table 1, Supplemental Table
6). The pathway analysis implicates multiple speciﬁc pathways
involved in the development of RA (Table 6). The top pathway
implicates neuroendocrine defects, speciﬁcally in the secretion of
macrophage migration inhibitory factor in the development of RA.
Macrophage abundance signiﬁcantly correlates with RA severity [28],
and polymorphisms in the MIF promoter are signiﬁcantly associated
with early onset RA [28]. We ﬁnd that genetic lesions affecting
signaling proteins upstream of the release of MIF from pituitary cells,
speciﬁcally GNG2, ADCY2, PRKCA, and ITPR3, are likely to increase MIF
release, as elevated MIF levels are associated with RA [29]. Upon
binding to receptors in macrophages, the PU.1 transcription factor,
required for the expression of a variety of inﬂammatory factors, is
activated. Phosphorylation by casein kinase 2 enhances the transacti-
vation activity of PU.1 [30] and is identiﬁed as another associated gene
in this pathway (CSNK2B). These four members, or a subset of these
four members, GNG2, ADCY2, PRKCA, and ITPR3, are implicated in
other signiﬁcant pathways as well, suggesting a common genetic
foundation for other signaling pathways with known roles in RA
pathogenesis, such as prostaglandin E2 signaling [31].
Expanding upon this genetic foundation, additional genes in
calcium channels CACNG1 and CAMK2D, and the MEF2B transcription
factor further implicate IP3 signaling, cAMP signaling, G-protein
signaling, and calcium signaling as general signaling pathways
disturbed in RA. These pathways play roles in other well-known RA-
related biochemical disturbances such as modulation of immune
functions in T lymphocytes and prostacyclin synthesis [32]. Additional
associated genes implicate speciﬁc pathways that are likely to be
differentially affected in different RA cases. For example, an additional
gene in monocyte chemoattractant protein 1 (CCL2), implicated in
leukocyte migration in the joint [33], suggests another mechanism
through which the GNG2, ADCY2, PRKCA, and ITPR3 may be involved
in the development of RA. Associated genes for of MHC class II
proteins, long known to underlie RA pathogenesis [34], with
additional genes IL2RA, IL2RB, and CD40, contribute to aberrant
signaling between immune cells and are clearly associated with RA in
our study.
Another aspect of RA that shows a genetic component in our
analysis is the expansion of neovascular networks into joints and the
role of these neovascular networks in bringing inﬂammatory cells into
joints. Again, the factors discussed above play a signiﬁcant role, with
additional genes VCAM (VCAM1) and EGFR indicating pathways
Table 8
Signiﬁcantly overrepresented pathways for the type II diabetes GWAS
Pathway p-value
Regulation of lipid metabolism_GNAQ regulation of lipid metabolism 0.0004
G-protein signaling_G-Proteins mediated regulation MAPK14
and JNK signaling
0.004
Development_Angiotensin activation of Akt 0.02
Development_Endothelin-1/EDNRA signaling 0.03
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signaling, [36] and crosstalk between the two pathways. Additional
associated genes alpha-catenin (CTNNA3) and ZO-1 (TJP1) suggest
that genetic defects in cell barrier integrity contribute to vascular
permeability and the inﬁltration of inﬂammatory cells into joints.
Other pathways implicated by our analysis, whichmay play a novel
role in RA, but whose signiﬁcance is unclear, are EDNRB signaling
(hits: GUCY1A2, PRKG1) and PKA cytoskeletal reorganization (hits:
AKAP13). Notably, EDNRB is downregulated in RA, providing some
validation that this may be a true pathogenic pathway in RA [37].
Recently, AKAP13 was discovered as a regulatory factor of TLR2
signaling [38] and is likely to provide hints into the genetic connection
between toll-like receptor signaling and RA [39].
Type 1 diabetes
Type 1 Diabetes (T1D) is an early onset autoimmune disorder. As
with RA, autoimmune diseases dominate the disease pathways, and
immune functions dominate the processes, identiﬁed by our analysis
of the most strongly associated genes with the T1D data (Supple-
mental Table 1 and Supplemental Table 7). Many genes previously
described as having associations with T1D arose in our analysis
including, MHC pathways, T lymphocyte pathways, interleukin 2
signaling pathways, and ERBB3 signaling pathways. Outside of these
known single-gene associations, we ﬁnd additional associated genes
CCR3, IL2, NFATC1, TAP1 and TAP2 antigen peptide transporters,
PSMD14 and PSMD9 proteasomes, AREG, NRG2, and NRG3 neuregu-
lins (ERBB signaling mediators), all of which participate in pathways
where the major players (i.e. the IL2 receptor, MHC proteins, and
ERBB3 receptor) have already been associated with T1D (see Table 7).
A large degree of overlap between T1D and RA GWAS results, as
indicated by the high degree of correlation in Table 1, is also observed.
Namely, overrepresented pathways involving IP3 receptors (ITPR1 and
ITPR3), calcium channels (CACNA2D3), MEF2A, CAMK2D, and GNG2
suggest a similarity in the genetic perturbations underlying these
diseases and, therefore, comparable immunological dysfunctions
characteristic of the two conditions. Additional associated genes
include STAT3, TNF, and a series of protein kinases (RAF1, MAPK14),
which may explain some of the vascular complications associated
with diabetes and JAK/STAT signaling augmented by angiotensin [40].Table 7
Signiﬁcantly overrepresented pathways for the type I diabetes GWAS
Pathway p-value
Immune response _NF-AT signaling and leukocyte interactions 9.89E-05
Signal transduction_Calcium signaling 0.002
Immune response _Antigen presentation by MHC class I 0.003
Immune response _Function MEF2 in T lymphocytes 0.004
Signal transduction_IP3 signaling 0.005
Cell cycle_Role of Brca1 and Brca2 in DNA repair 0.007
Immune response _IL2 activation and signaling pathway 0.008
Development_G-Proteins mediated regulation MARK-ERK signaling 0.01
Development_ERBB-family signaling 0.01
Development_Angiotensin activation of Akt 0.01
Immune response _Histamine signaling in dendritic cells 0.02
Development_Angiotensin signaling via STATs 0.02
Signal transduction_Activation of PKC via G-Protein coupled receptor 0.02
Development_Angiotensin activation of ERK 0.02
Immune response _CCR3 signaling in eosinophils 0.02
Immune response _Histamine H1 receptor signaling in immune response 0.02
Immune response _Role of DAP12 (TYROBP) receptors in NK cells 0.02
Development_Endothelin-1/EDNRA signaling 0.02
Development_Alpha-1 adrenergic receptors activation of ERK 0.04
Immune response _PGE2 signaling in immune response 0.04
Chemotaxis_CXCR4 signaling pathway 0.04
Development_EDNRB signaling 0.05
Immune response _NTS activation of IL8 in colonocytes 0.05
Immune response _Antigen presentation by MHC class II 0.05While immune pathways were to be expected to be overrepre-
sented among T1D associated genes, an extremely provocative
associationwith BRCA1 DNA repair was also observed and is discussed
further in the Supplemental Text.
Type 2 diabetes
Type 2 diabetes (T2D) is a metabolic disorder strongly associated
with obesity, and is characterized by defects in glucose uptake in
response to insulin. Our pathway analysis of T2D identiﬁed a small
number of overrepresented pathways, although a number of inter-
esting process defects were observed (see Table 8). The top signiﬁcant
pathway, regulation of lipid metabolism, has obvious implications for
obesity. Gene members of this pathway among the most strongly
associated with T2D include PPARG, which has already been
implicated by multiple genome-wide association studies. Down-
stream of PPARG, apolipoprotein C (APOC1), which is important for
lipid metabolic processes, was found to be one of the genes most
strongly associated with T2D. Upstream of PPARG we observe the
associated genes PLCB1, PRKCE, and PLA2G4A, all of which respond to
nicotinic G-protein coupled receptors. Other associated genes in G-
protein coupled receptor pathways, including BLNK, VAV2, and
ARHGEF12, potentially alter signaling through numerous G-protein
coupled receptor subtypes, of which at least types q and I signal
through CDC42, another pathway hit. These parallel G-protein
signaling pathways activate CDC42 and JNK (MAPK8), resulting in
insulin resistance [41]. Furthermore, these pathways are modulated
by signaling through long chain fatty acids, such as arachidonic acid, as
well as diacylglycerol, and with the addition of calcium signaling
through CAMK2D, all converge upon AKT signaling, which is also
implicated in our analysis and plays a crucial role in promoting glucose
uptake in response to insulin [42].
A connection between neurological diseases, especially Alzheimer
disease, and type 2 diabetes has been extensively cataloged in the
literature [43]. Our disease pathway results further suggest that genes
involved in neuronal disorders could also play a role in T2D
(Supplemental Table 1), and neural development processes are
overrepresented among the most strongly associated T2D genes
(Supplemental Table 8). β-cells are known to share a large number of
similarities with neuronal cells due to the absence of neuron-
restrictive silencing factor in insulin-producing cells [44]. TCF7L2
(TCF4), strongly associated with T2D, is also involved in the
development of neuronal cells [45] and the pituitary gland [46].
Thus, our analysis suggests that β-cell developmental pathways,
which share similarities to neuronal developmental signaling path-
ways (especially Wnt signaling), are likely to play a large role in T2D
predisposition.
Discussion
Our analysis of the most strongly associated genes arising from the
GWAS analysis of seven different diseases identiﬁed statistically
signiﬁcant evidence, along with biological plausibility, for pathogenic
pathways involved in each. Some of these pathways are presumed to
play a role in disease pathogenesis though variations in speciﬁc genes
that have not yet been identiﬁed via standard single-locus-based
1 SAS Institute, Cary, NC, USA.
2 GeneGO Inc., Encinitas, CA, USA.
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results strongly suggest that common human diseases are modulated
by a large number of low-risk genetic factors (“polygenes”), which are
not likely to be easily identiﬁed through the use of standard single-
locus-oriented univariate GWAS analysis techniques. This is not
counterintuitive with the data, considering that only a small number
of genetic variations associated with disease at genome-wide
signiﬁcance levels (with relative risks greater than 1.3) have been
identiﬁed by current GWAS initiatives, and considering the miniscule
proportion of the disease burden explained by these identiﬁed
variations. Pathway analysis is an extremely useful approach for
extending current single-locus-oriented, univariate GWAS analysis
techniques, since it seeks to extract large amounts of biologically
relevant information from them. Although many variations in the
genes we have identiﬁed in our analyses could possibly be identiﬁed
in extremely large case/control GWAS initiatives, a pathway analysis of
smaller studies is a much more efﬁcient approach to identifying
candidate risk factors and may be a useful method for identifying
speciﬁc genes for follow-up or replication studies. It should be noted
that “a small GWAS” is a relative term, corresponding to 2000 cases
per disease, which still translates into a signiﬁcant ﬁnancial invest-
ment that should be thoroughly leveraged to maximize its yield.
Our analyses strongly suggests that the pathogenic processes
underlying susceptibility to any single common chronic condition are
common across many diseases, and that the development of any
particular disease phenotype is likely to be a function of multiple
interacting general and speciﬁc risk factors. Most of the seven diseases
in the WTCCC appear to be mediated by relatively weak risk factors in
sets of general signaling strategies, including G-protein, adenylate
cyclase, protein kinase A and C, IP3, and calcium signaling mechan-
isms. These common risk factors are likely to underlie general
morbidity and form the basis for the strong genetic similarity
observed across what, on the surface, appear to be unrelated diseases.
Built on top of these basic signaling risk factors are a wide variety of
disease-speciﬁc risk factors, a large number of which are transcription
factors, transcription regulatory factors, cell surface receptors, or other
cell surface structures such as antigen-presenting molecules. These
risk factors are likely to be the driving force underlying the
development of a speciﬁc disease phenotype over another.
Additionally, each disease appears to bemediated by at least two of
three basic cellular functions: metabolic, neurological, or inﬂamma-
tory processes. These connections are best described in the context of
surprising similarities among the diseases. One would not have
anticipated that bipolar disorder would be demonstrated to have
underlying pathways in common with CAD and T2D. While neurolo-
gical functions were to be expected in the pathogenesis of BD, it is
clear that lipid metabolism may also play an important role. HDL
metabolism, speciﬁcally affecting ApoB, was predicted to contribute to
BD. The high concentration of lipids within the nervous system, as
well as the expanding number of associations implicating lipid
metabolism deregulation to neurological disorders, such as ApoE
mutations in Alzheimer’s disease, or α-synuclein mutations in
Parkinson’s disease, conﬁrms this connection [47]. While lipid
metabolism has obvious implications for CAD and T2D, these diseases
are also connected to BD through neurological defects. The neurolo-
gical dysfunctions in CAD appear to stem from serotonin signaling and
formation of neuromuscular junctions or the role of neuronal proteins
after vascular injury. Both sources play an important regulatory role in
the migration of VSMC, a central process in the pathogenesis of CAD
[48,49]. The neurological connection in T2D appears to revolve around
the development of β-cells and is exempliﬁed by the strong
association of T2D with TCF7L2 polymorphisms, a transcription factor
recognized for its role in neural development before its association
with T2D [64]. Another surprisingly strong connection involves HT
with CD. In this case the connection of HT, considered a metabolic
disease, to CD likely lies in the role of inﬂammation in vascularremodeling [50]. Similarly, metabolic disorders have a clear role in
hypertension pathogenesis but also appear to play a role in CD. In CD,
there are known disturbances in lipid regulation, which may
contribute further to the inﬂammatory response and to development
of metabolic syndrome in CD patients [51].
Similarly surprising connections between seemingly unrelated
diseases have been observed previously, and many more will
undoubtedly be revealed by upcoming GWAS. For example,
myocardial infarction and macular degeneration, diseases whose
phenotypes are seemingly unrelated, have been connected by
susceptibility polymorphisms in CFH [52,53]. Myocardial infarction
has also been connected to other inﬂammatory diseases, such as
RA and multiple sclerosis, by MHC2TA polymorphisms [54].
Similarities between diseases are likely to reveal related patholo-
gical mechanisms, as has been observed in the case of Alzheimer’s
disease and T2D and may reveal therapeutic strategies effective
across multiple diseases [55].
Our analysis is limited by the incompleteness of genomic
coverage of the WTCCC and its lack of ability to discern structural
variants and other human genomic variation beyond commonly
occurring SNPs. However, the data and our pathway analysis and
interpretation of it provide a new perspective on how large human
genomic data set information can be processed to implicate the
role of biologic pathways that would otherwise be left unrecog-
nized and potentially show a convergence of disease mechanisms.
Thus, beyond replication of particular SNP associations arising from
future GWAS and sequencing studies, consideration and further
validation of pathway analysis may be a useful and insightful
research angle.
Methods
Basic pathway analyses
SNP data was downloaded from the WTCCC Web page (http://
www.wtccc.org.uk/) [8]. SNPs were assigned to genes within 5 kB
using Biomart (http://www.biomart.org/). SNPs mapping to multiple
genes were assigned to a single gene according to the following
hierarchy: codingN intronicN5’utrN3’utrN5’upstreamN3’upstream.
The statistical evidence for the most signiﬁcant SNP for each gene
was assigned as a weight for the corresponding gene in subsequent
analyses. This strategy avoids issues with weight inﬂation induced by
genes having different numbers of SNPs, multiple SNPs in LD within a
gene, or deﬂation of the weight of the gene frommultiple insigniﬁcant
SNPs. A total of 15,835 genes were assigned a weight in this manner.
Correlations between the p-values of these genes were generated
using both Pearson’s correlation coefﬁcients and Spearman’s correla-
tion coefﬁcients in JMP 5.11. Spearman’s correlations were used to
demonstrate that outliers did not drive the Pearson correlation
structure. Distances for the construction of a tree diagram were
calculated as one minus the Pearson correlation coefﬁcient computed
over the -log p-values of the SNPs associated with each gene. Log p-
values were used since they accentuate the weight difference for
slightly signiﬁcant vs strongly signiﬁcant genes. The tree diagramwas
generated using the neighbor joining method in MEGA 3.1 [56]. The
top 2.5% of genes with corresponding Entrez ID’s were entered into
MetaCore2 and tested for enrichment in Maps, Diseases, GO processes,
and GeneGO processes, separately for each disease. Metacore uses a
hypergeometric model to determine the signiﬁcance of enrichment. A
free trial of MetaCore is available at http://www.genego.com/
productTrials.php.
Fig. 1. Tree diagram of diseases based upon the distances calculated as one minus the
correlation coefﬁcient between each disease. BD=bipolar disorder, CAD=coronary
artery disease, T2D=type 2 diabetes, HT=hypertension, CD=Crohn’s disease, RA=rheu-
matoid arthritis, T1D=type 1 diabetes. The analysis suggests three classes of diseases
(see Discussion), differing from commonly accepted classiﬁcations.
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ranking of genes
To demonstrate that the pathways identiﬁed by our analyses are
signiﬁcant ﬁndings, rather than occurring by chance, the bottom or
lowest-ranking 2.5% of genes were subject to the same analysis as the
top or highest-ranking 2.5% genes (Supplemental Table 9). In almost
all cases, the pathways enriched in these analyses had no known or
obvious biological association with the diseases in question. In fact,
cell cycle and oxidative phosphorylation pathways are apparently
unaffected across all diseases from our analyses, suggesting that basic
cellular processes are conserved in these disease states. However, the
analysis of rheumatoid arthritis implicated a number of pathways
involved in disease pathogenesis. The common thread connecting
these immune system pathways, along with some of the non-
immune-system pathways, are hits in transcription factors RelA and
c-Fos. The activities of these transcription factors are required for RA
pathogenesis [57], their inhibition reduces inﬂammation [58,59], and
their overexpression promotes tumorigenicity [60,61]. Although these
proteins are involved in RA pathogenic pathways, it is not surprising
that they are found among those genes not involved in RA
pathogenesis. However, this indicates that care should be taken in
the interpretation of pathway analysis, and deceptive false positive
results are a possibility. On the other hand, the consistency and
credibility of our results across multiple diseases indicate that such
misleading false positive results are likely to be rare.
Statistical validation of the correlation analysis results between diseases
To demonstrate that the correlations between the diseases are not an
artifact arising from the WTCCC’s use of common controls for all seven
GWAS studies, we conducted a simulation study to determine the effect
that the use of common controls would have on such correlations in an
idealized case. The simulation was structured as follows: the number of
genes and number of SNPs per gene were selected to match the WTCCC
data. For each SNP a randomly determined allele frequency between 0.05
and 0.95 was selected. This frequency was used to randomly assign
genotypes to 3,000 individuals per control group. Seven separate control
groupswere generated in this manner. Seven unique disease populations,
composed of 2,000 members each, were generated by maintaining the
same control genotype frequency per SNP within each disease popula-
tion, with the addition of 5% probability per SNP that the genotype
frequency would differ by ±5% relative to the controls. Therefore, minor
allele variance at disease loci ranged from 5% vs 10% (amounting to an
odds ratio of 2.11) in cases vs controls, to 45% vs 50% in cases vs controls
(amounting to an odds ratio of 1.22). A p-value for each disease compared
to each of the seven controls was then calculated. The negative log of the
most signiﬁcant SNP per gene was then assigned as the weight of that
gene, as done in our WTCCC analyses.
The simulation allows three types of comparisons: 1. the correlation
between a single disease and its gene weights as determined by
comparison to multiple control groups; 2. the correlation between
different diseases and their geneweights as determined by comparison to
identical controls; and 3. the correlation between different diseases and
their geneweights as determined by comparison to different controls. For
each set of correlations, 95% conﬁdence intervals were then calculated,
and the results are as follows: 1. the average correlation in GWAS
results when the same case group is used but with different controls is
r2=0.955±0.0001 (n=7350); 2. the average correlation between GWAS
results when different case groups are used with the same control group
is r2=0.391±0.014 (n=4200); and 3. the average correlation when
different case groups with different control groups are used is r2=0.388
±0.014 (n=47,250). In our idealized case it is clear that any baseline
correlation between diseases is due to the similarity in non-disease-gene
genotype frequencies as determined by the increase in correlation
between diseases using different control groups or the same controlgroup (Δr2≈0.003), while a strong correlation is observed if the same case
group is compared to multiple independent control groups. Due to
population heterogeneity, baseline correlations in theWTCCC data can be
expected to be, and are observed to be, much lower than those observed
in our idealized simulation study, while some of the between-disease
correlations in theWTCCCdata approach the level of correlation observed
between identical case groups and different control groups, at least on the
basis of our simulation studies. This lends strong evidence that our
observed correlations are not mere artifacts, but rather reﬂect true GWAS
results similarities between different diseases, and is further conﬁrmed by
the pathway similarity observed between these diseases.
To correct for p-value deﬂation due to mapping of multiple SNPs to
a gene, we conducted a simulation study to determine the effect on
the p-value resulting from selecting the lowest p-value from multiple
SNPs, with equal frequency in case and control populations, mapping
to a single gene in an idealized case. The simulation was structured as
follows: 509 genes with 1 through 509 SNPs mapping to each gene
were simulated. For each SNP a randomly determined allele frequency
between 0.05 and 0.95 was selected. This frequency was used to
randomly assign genotypes to 3000 individuals per control group and
2000 individuals per case group. A p-value for each SNP was then
calculated, selecting the lowest p-value per gene. This process was
repeated 500 times to determine the average p-value assigned to a
gene with 1 through 509 SNPs mapping to it, and a correction factor
was determined based upon the decrease in average p-value when
more than one SNP mapped to a single gene.
To assess the overall similarity of the GWAS results across all the
diseases, oneminus the correlation coefﬁcient between the GWAS results
for each disease was used as a measure of distance to create a tree
diagram. Thismeasurewas chosen so that perfectly correlated datawould
correspond to no distance between diseases, increasing to a maximum
distance of one between completely uncorrelated data. There appears to
be three broad disease groupings, as shown in Fig. 1. The ﬁrst group, BD,
CAD, and T2D, is composed of diseases with strong neurological and
metabolic components. The second group, with RA and T1D, is composed
of diseases that are primarily autoimmune disorders. Finally, the third
group, with CD and HT, are intermediate disorders with inﬂammatory,
neurological, and metabolic aspects. This genetic categorization differs
from commonly accepted categorizations, i.e., BD on its own; CAD, T2D,
and HT as metabolic disorders; and RA, T1D, and CD as autoimmune
disorders. Thus, potential common genetically mediated, pleiotropic,
etiologic mechanisms may shed new light on disease classiﬁcation.
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